User:Mr. Ibrahem/Vorinostat

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Vorinostat
Clinical data
PronunciationVorinostat /vɒˈrɪnoʊstæt/ vorr-IN-oh-stat
Zolinza (/zoʊˈlɪnzə/ zoh-LIN-zə
Trade namesZolinza, Vorinostat MSD, others
Other namesSuberanilohydroxamic acid (SAHA)
AHFS/Drugs.comMonograph
MedlinePlusa607050
License data
Routes of
administration		By mouth (capsules)
Drug classHistone deacetylase inhibitors (HDI)[1]
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability1.8–11%[2]
Protein binding~71%
MetabolismLiver glucuronidation and β-oxidation
CYP system not involved
Metabolitesvorinostat O-glucuronide, 4-anilino-4-oxobutanoic acid (both inactive)[3]
Elimination half-life~2 hours (vorinostat and O-glucuronide), 11 hours (4-anilino-4-oxobutanoic acid)
ExcretionKidney (negligible)
Identifiers
  • N-Hydroxy-N'-phenyloctanediamide
Chemical and physical data
FormulaC14H20N2O3
Molar mass264.325 g·mol−1
3D model (JSmol)
  • O=C(Nc1ccccc1)CCCCCCC(=O)NO
  • InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18) checkY
  • Key:WAEXFXRVDQXREF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Vorinostat, sold under the brand name Zolinza, is a medication used for cutaneous T cell lymphoma (CTCL).[1] Specifically it is used when the disease persists, gets worse, or comes back during or after two other treatments.[1] It is taken by mouth.[1]

Common side effects include diarrhea, tiredness, change in taste, low platelets, hair loss, cough, and fever.[1] Other severe side effects may include blood clots and high blood sugar.[1] Use during pregnancy may harm the baby.[1] It is a histone deacetylase inhibitors (HDI).[1]

Vorinostat was approved for medical use in the United States in 2006.[1] While it was given orphan medication status in Europe in 2004, in 2009 the application for approval was withdrawn.[4] In the United States it costs about 14,600 USD per month as of 2021.[5]

References[edit]

  1. ^ a b c d e f g h i j k l "Vorinostat Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2016. Retrieved 16 September 2021.
  2. ^ "Withdrawal Assessment Report for Vorinostat MSD 100 mg Hard Capsules (vorinostat)" (PDF). European Medicines Agency. 23 October 2008. p. 9. Archived (PDF) from the original on 15 September 2016. Retrieved 1 September 2016.
  3. ^ "Zolinza (vorinostat) Capsules. Full Prescribing Information" (PDF). Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Archived (PDF) from the original on 2 October 2016. Retrieved 1 September 2016.
  4. ^ "Vorinostat MSD: Withdrawal of the marketing authorisation application". Archived from the original on 22 September 2021. Retrieved 16 September 2021.
  5. ^ "Zolinza Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 14 June 2016. Retrieved 16 September 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Vorinostat&oldid=1211404880"